Midostaurin approved for FLT3-mutated AML
M Levis - Blood, The Journal of the American Society of …, 2017 - ashpublications.org
Midostaurin was recently approved by the US Food and Drug Administration for the
treatment of FLT3-mutant acute myeloid leukemia (AML). This is the first drug to receive …
treatment of FLT3-mutant acute myeloid leukemia (AML). This is the first drug to receive …
Therapeutic targeting of FLT3 and associated drug resistance in acute myeloid leukemia
Acute myeloid leukemia (AML) is a heterogeneous disease caused by several gene
mutations and cytogenetic abnormalities affecting differentiation and proliferation of myeloid …
mutations and cytogenetic abnormalities affecting differentiation and proliferation of myeloid …
Single-cell RNA-seq reveals AML hierarchies relevant to disease progression and immunity
Acute myeloid leukemia (AML) is a heterogeneous disease that resides within a complex
microenvironment, complicating efforts to understand how different cell types contribute to …
microenvironment, complicating efforts to understand how different cell types contribute to …
Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia
Patients with acute myeloid leukemia (AML) harboring FLT3 internal tandem duplications
(ITDs) have poor outcomes, in particular AML with a high (≥ 0.5) mutant/wild-type allelic …
(ITDs) have poor outcomes, in particular AML with a high (≥ 0.5) mutant/wild-type allelic …
Targeting glutamine metabolism and redox state for leukemia therapy
MA Gregory, T Nemkov, HJ Park, V Zaberezhnyy… - Clinical Cancer …, 2019 - AACR
Purpose: Acute myeloid leukemia (AML) is a hematologic malignancy characterized by the
accumulation of immature myeloid precursor cells. AML is poorly responsive to conventional …
accumulation of immature myeloid precursor cells. AML is poorly responsive to conventional …
Knowledge-primed neural networks enable biologically interpretable deep learning on single-cell sequencing data
N Fortelny, C Bock - Genome biology, 2020 - Springer
Background Deep learning has emerged as a versatile approach for predicting complex
biological phenomena. However, its utility for biological discovery has so far been limited …
biological phenomena. However, its utility for biological discovery has so far been limited …
Cell metabolism and DNA repair pathways: implications for cancer therapy
T Sobanski, M Rose, A Suraweera… - Frontiers in cell and …, 2021 - frontiersin.org
DNA repair and metabolic pathways are vital to maintain cellular homeostasis in normal
human cells. Both of these pathways, however, undergo extensive changes during …
human cells. Both of these pathways, however, undergo extensive changes during …
The current landscape of single-cell transcriptomics for cancer immunotherapy
Immunotherapies such as immune checkpoint blockade and adoptive cell transfer have
revolutionized cancer treatment, but further progress is hindered by our limited …
revolutionized cancer treatment, but further progress is hindered by our limited …
[HTML][HTML] Therapeutic targeting of FLT3 in acute myeloid leukemia: current status and novel approaches
M Tecik, A Adan - OncoTargets and Therapy, 2022 - ncbi.nlm.nih.gov
FMS-like tyrosine kinase 3 (FLT3) is mutated in approximately 30% of acute myeloid
leukemia (AML) patients. The presence of FLT3-ITD (internal tandem duplication, 20–25%) …
leukemia (AML) patients. The presence of FLT3-ITD (internal tandem duplication, 20–25%) …
Tyrosine kinase inhibitor–induced defects in DNA repair sensitize FLT3 (ITD)-positive leukemia cells to PARP1 inhibitors
S Maifrede, M Nieborowska-Skorska… - Blood, The Journal …, 2018 - ashpublications.org
Mutations in FMS-like tyrosine kinase 3 (FLT3), such as internal tandem duplications (ITDs),
can be found in up to 23% of patients with acute myeloid leukemia (AML) and confer a poor …
can be found in up to 23% of patients with acute myeloid leukemia (AML) and confer a poor …